JNCCN 360

Editor:

David S. Ettinger, MD

Advertisement

Advertisement

Solange Peters, MD, PhD, on Managing Toxicities of Checkpoint Inhibitors and Chemotherapy Regimens in NSCLC

Cristina Merkhofer, MD, MHS, on NSCLC: Monitoring Patients in Lieu of Clinical Trials

Suresh S. Ramalingam, MD, on Comparing Maintenance Therapies in Non–Small Cell Lung Cancer: Less May Be More

Recent

Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer

PET Imaging of Mitochondrial Activity in Lung Tumor Cells

FLAURA Trial: Overall Survival With Osimertinib in EGFR-Mutated Lung Cancer

Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?

Published

Medical Literature

Are Patients Older Than 90 Candidates for Lung Cancer Treatment?

Pemetrexed and Carboplatin Plus TKI in Advanced EGFR-Mutant Lung Cancer

Early-Phase Studies of Entrectinib for the Treatment of NTRK Fusion–Positive Solid Tumors

Role of Bevacizumab in Patients With Advanced NSCLC With Liver Metastases

Ongoing

Proceedings from the 15th Annual Winter Lung Cancer Conference

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care-Lung Cancer: Advanced Disease

Available

Clinical Trials

Mayo Clinic Cancer Center

Yale Cancer Center / Smilow Cancer Hospital

Moffitt Cancer Center

Vanderbilt-Ingram Cancer Center

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.